You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Govt recommends nod to SII for phase 2/3 trials of Covovax on children

An expert panel of India's Central Drug Authority recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on children aged 2 to 17 years

Topics
Coronavirus Vaccine | clinical trials | Health Ministry

Press Trust of India  |  New Delhi 

coronavirus, vaccine, vaccination, covid-19

An expert panel of India's Central Drug Authority on Tuesday recommended granting permission to (SII) for conducting phase 2/3 trials of Covid vaccine Covovax on children aged 2 to 17 years with certain conditions, official sources said.

The trials would cover 920 children, 460 each in the age-group of 12-17 and 2-11 across 10 sites.

"The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) deliberated on the revised study protocol application given by SII on Tuesday and recommended granting permission to the firm for conducting phase 2/3 trial of Covovax on children aged 2 to 17 years," a source said.

The Pune-based pharmaceutical company had submitted a revised protocol for inclusion of pediatric cohort in the ongoing Covovax phase 2 and 3 observer-blind, randomised, controlled study in Indian adults aged 18 years and above to determine the safety and immunogenicity of the jab.

In the revised application submitted last week, SII director (government and regulatory affairs) Prakash Kumar Singh and director Dr Prasad Kulkarni stated that globally, all adults aged 18 and above are being vaccinated and after this population is protected against COVID-l9, children will remain the most susceptible group.

"There have been reports of severe disease, including deaths in vulnerable children. It has also been predicted that the third wave of the pandemic may affect children in the country.

"Moreover, until all age groups, including children are covered under vaccination. the SARS-CoV-2 virus may remain in circulation, thus keeping everyone at risk of severe disease," they said in the letter.

Considering all these factors, several companies have already started evaluating the safety and immunogenicity of COVID-19 vaccines in the pediatric population, the SII has stated.

Union Health Minister Mansukh Mandaviya on Tuesday told BJP MPs that Covid vaccination for children is likely to start soon, sources said.

During the BJP parliamentary party meeting, he said that the Covid vaccination drive is going on in full swing in the country.

Currently, only those who are 18 or above are eligible for vaccination against the coronavirus. Very soon a vaccine is expected for children and inoculation for them will start, the sources quoted the minister as telling the MPs.

The SII is learnt to have informed that their collaborator, Novavax, Inc., US has already generated a large amount of data in adults in different countries and that the safety, efficacy and immunogenicity data on the Novavax COVID-I9 vaccine are very robust which includes a safety database of more than 50000 adults with data from Australia, South Africa, UK and USA and preliminary safety data in 2248 children.

"Further in the ongoing Phase 2/3 study in India, more than 1400 participants have received at least first dose of the vaccine with no safety concerns reported so far," the application stated.

"This will ensure that a life saving vaccine can be brought at the earliest for our pediatric population also in addition to the adult population immediately after grant of Emergency Use Authorisation.

"This approval will ensure an early availability of COVID-19 vaccine for children of our country in line with our prime minister's clarion call Atmanirbhar Bharat and will help in faster elimination of the COVID-19 pandemic," Singh mentioned in the application.

The SEC on June 30 had recommended against granting permission to SII for conducting phase 2 and 3 trial of Covovax on children aged 2 to 17 years following which the company had submitted a revised study protocol last week.

In August 2020, US-based vaccine maker Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, July 27 2021. 22:13 IST
RECOMMENDED FOR YOU